Dr. Li is an associate chief physician in the department of Breast Oncology at Sun Yat-sen University Cancer Center. He is a graduate student supervisor of Sun Yat-sen University. He engaged in surgery-based multidisciplinary treatment and medical case management of breast cancer, including surgical treatment, chemotherapy, endocrine therapy, targeted therapy and related basic research. Specialty: radical surgery of breast cancer, breast-conserving surgery, and breast reconstruction. He is thesecretary general of the Guangdong Association of Study of Thoracic Oncology. Awards: 2016 GASTO Young Outstanding Talent Award; 2019 National Breast Cancer MTB Case Competition Champion; 2019 GASTO Clinical Research Award of the Year; 2022 Outstanding Young and Middle School Teacher Award of Guangdong Ke-Lin Medical Education Foundation; 2023 GASTO Annual Research Paper Award.

Tumor-targeted therapy and drug resistance mechanism.

2011-2014, Master’s Degree in Oncology, Sun Yat-sen University, China;

2014-2017, Ph.D. in Oncology, Sun Yat-sen University, China.

Selected publications

1 Yang, Lu#; Li, Ning#; Xue, Zhicheng#; Liu, Ling-Rui; Li, Jian; Huang, Xiaojia; Xie, Xinhua; Zou, Yutian; Tang, Hailin*; Xie, Xiaoming*. Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer. Cell Death and Differentiation, 2020, 27(07): 2066-2080.

2 Xiong, Zhenchong#; Yang, Lin#; Li, Ning#; Fu, Jianchang; Liu, Peng; Sun, Peng; Wei, Weidong*; Xie, Xiaoming*. DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. Clinical and Translational Medicine, 2022, 12(12): 0-e1133.  

3 Ou, Wei#; Li, Ning#; Wang, Bao-Xiao#; Zhu, Teng-Fei; Shen, Zhi-Lin; Wang, Tao; Chang, Wu-Guang; Chang, Zeng-Hao; Hu, Xin-Xin; Pu, Yue; Ding, Lie-Ming; Wang, Si-Yu*. Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial. EClinicalMedicine, 2023, 03(57): 0-101839.  

4 Li, Ning#; Feng, Lin#; Han, Hui-Qiong; Yuan, Jing; Qi, Xue-Kang; Lian, Yi-Fan; Kuang, Bo-Hua; Zhang, Yu-Chen; Deng, Cheng-Cheng; Zhang, Hao-Jiong; Yao, You-Yuan; Xu, Miao; He, Gui-Ping; Zhao, Bing-Chun; Gao, Ling; Feng, Qi-Sheng; Chen, Li-Zhen; Yang, Lu; Yang, Dajun*; Zeng, Yi-Xin*. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis. Cancer Letters, 2016, 381(01): 14-22.  

5 Li, Ning#; Yang, Lu#; Qi, Xue-Kang; Lin, Yu-Xin; Xie, Xinhua; He, Gui-Ping; Feng, Qi-Sheng; Liu, Ling-Rui; Xie, Xiaoming; Zeng, Yi-Xin*; Feng, Lin*. BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc. Cell Death & Disease, 2018, 09(07): 0-761.  

6 Li, Ning#; Zeng, Zhi-Fan#; Wang, Si-Yu*#; Ou, Wei; Ye, Xiong; Li, Jian; He, Xiao-Hua; Zhang, Bin-Bin; Yang, Hua; Sun, Hai-Bo; Fang, Qin; Wang, Bao-Xiao. Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Annals of Oncology, 2015, 26(03): 504-509.  

7 Li, Ning#; Wang, Bao-Xiao#; Li, Jian#; Shao, Yang; Li, Ming-Tian; Li, Jian-Jun; Kuang, Peng-Peng; Liu, Zui; Sun, Tian-Yu; Wu, Hui-Qi; Ou, Wei*; Wang, Si-Yu*. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer. Cancer, 2022, 128(04): 708-718.  

Updated by International Office, Sun Yat-sen University Cancer Center